Y-Intercept (HK)’s Corbus Pharmaceuticals CRBP Stock Holding History

Y-Intercept (HK)’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-22,646	Closed	-$212K	–	1656
2026 Q2	$212K	Buy	+22,646	New	+$214K	﹤0.01%	1563
2025 Q3	–	Sell	-20,437	Closed	-$141K	–	1638
2025 Q2	$141K	Buy	+20,437	New	+$148K	﹤0.01%	1505
2024 Q4	–	Sell	-18,372	Closed	-$379K	–	1262
2024 Q3	$379K	Buy	+18,372	New	+$940K	0.02%	915
2021 Q3	–	Sell	-682	Closed	-$37K	–	690
2021 Q2	$37K	Buy	+682	New	+$37.8K	0.01%	568

Other funds holding CRBP

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Doliver Advisors Houston, Texas $458M AUM 38.24% 1-Year Est. Return

Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Pinnacle Wealth Planning Services Mansfield, Ohio $1.03B AUM 22.32% 1-Year Est. Return

Y-Intercept (HK)'s CRBP Position: Q3 2026 in Review

Y-Intercept (HK) sold out of Corbus Pharmaceuticals (CRBP) in Q3 2026, closing a stake of 22,646 shares — an estimated $212K sold.

Y-Intercept (HK) first reported a position in CRBP in Q2 2021 and held it in 4 quarters. The position peaked at $379K in Q3 2024. 36 funds tracked by Wall St. Rank hold CRBP as of Q3 2026.

Y-Intercept (HK) reported no remaining Corbus Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
Y-Intercept (HK) sold 22,646 Corbus Pharmaceuticals shares in Q3 2026, an estimated $212K.
Y-Intercept (HK) first reported a position in Corbus Pharmaceuticals in Q2 2021 and held it in 4 quarters.
Y-Intercept (HK)'s Corbus Pharmaceuticals position peaked at $379K in Q3 2024.
36 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.